Get Level 2

Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Glaxosmithkline Share Price
  4. Glaxosmithkline Share Regulatory News
  5. Block Listing Application

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Glaxosmithkline Information

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1950.00    -7.50 (-0.38%)
Bid:
1954.50
Ask:
1955.00
Spread: 0.50 (0.026%)
Market Cap: £78.13b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Block Listing Application

11 Dec 2025 09:00

RNS Number : 0709L
GSK PLC
11 December 2025
 

 

Issued: 11 December 2025, London UK

 

Block Listing Application

 

 

Application has been made to the Financial Conduct Authority and the London Stock Exchange plc for a total of 250,000 Ordinary Shares of 31¼p each ('Shares') to be admitted to the Official List.

 

The Shares are being reserved under a block listing and will be issued under the GlaxoSmithKline plc Share Save Plan 2022.

 

When issued, the Shares will rank pari passu with the existing Ordinary Shares of 31¼p each.

 

Admission is expected to be effective on 12 December 2025.

 

 

 

 

V A Whyte

Company Secretary

 

11 December 2025

 

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ALSPKKBDABDDFBD
12345678910
Date   Source Headline
9th Mar 20263:00 pmRNSBoard Committee Change
9th Mar 20267:00 amRNSGSK and Alfasigma agree global linerixibat rights
9th Mar 20267:00 amRNSTransaction in Own Shares
6th Mar 20262:21 pmRNSFiling of GSK plc 2025 Annual Report on Form 20-F
6th Mar 20267:00 amRNSTransaction in Own Shares
5th Mar 202610:00 amRNSGSK publishes Annual Report 2025
5th Mar 20267:00 amRNSTransaction in Own Shares
4th Mar 20263:30 pmRNSDirector/PDMR Shareholding
4th Mar 20267:00 amRNSTransaction in Own Shares
3rd Mar 20263:00 pmRNSGSK completes acquisition of RAPT Therapeutics
3rd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20263:00 pmRNSTotal Voting Rights
2nd Mar 20267:00 amRNSTransaction in Own Shares
27th Feb 20263:30 pmRNSDirector/PDMR Shareholding
27th Feb 20267:00 amRNSTransaction in Own Shares
26th Feb 20267:05 amRNSLinerixibat accepted for priority review in China
26th Feb 20267:00 amRNSBepirovirsen accepted for Japan regulatory review
26th Feb 20267:00 amRNSTransaction in Own Shares
25th Feb 20264:54 pmRNSDirector/PDMR Shareholding
25th Feb 20263:30 pmRNSDirector/PDMR Shareholding
25th Feb 20267:00 amRNSGSK enters agreement to acquire 35Pharma
25th Feb 20267:00 amRNSTransaction in Own Shares
24th Feb 20263:30 pmRNSDirector/PDMR Shareholding
24th Feb 20267:00 amRNSTransaction in Own Shares
23rd Feb 20267:00 amRNSTransaction in Own Shares
20th Feb 20263:30 pmRNSDirector/PDMR Shareholding
20th Feb 20267:00 amRNSTransaction in Own Shares
19th Feb 20263:30 pmRNSDirector/PDMR Shareholding
19th Feb 20267:00 amRNSTransaction in Own Shares
18th Feb 20267:00 amRNSTransaction in Own Shares
17th Feb 20263:30 pmRNSDirector/PDMR Shareholding
17th Feb 20263:30 pmRNSDirector/PDMR Shareholding
17th Feb 20267:00 amRNSGSK - fourth tranche of share buyback programme
17th Feb 20267:00 amRNSExdensur approved by the European Commission
16th Feb 20263:30 pmRNSDirector/PDMR Shareholding
16th Feb 20263:30 pmRNSDirector/PDMR Shareholding
16th Feb 20263:30 pmRNSDirector/PDMR Shareholding
11th Feb 20263:30 pmRNSDirector/PDMR Shareholding
11th Feb 20263:30 pmRNSDirector/PDMR Shareholding
11th Feb 20263:30 pmRNSDirector/PDMR Shareholding
11th Feb 20263:30 pmRNSDirector/PDMR Shareholding
10th Feb 20267:00 amRNSChina CDE accepts Arexvy adults 60+ application
9th Feb 20263:30 pmRNSDirector/PDMR Shareholding
6th Feb 202610:30 amRNSDirector/PDMR Shareholding
6th Feb 20267:00 amRNSNucala COPD approved by the European Commission
5th Feb 20263:30 pmRNSDirector/PDMR Shareholding
4th Feb 20267:00 amRNSFinal Results
2nd Feb 20263:00 pmRNSTotal Voting Rights
26th Jan 20267:00 amRNSEuropean Commission approves Arexvy for adults 18+
20th Jan 20267:05 amRNSGSK to acquire RAPT Therapeutics
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
FRA.US
Blackrock Floating Rate Income Strategies Fund Inc
CBOE
-0.46%
DRTY
DRTY.L
LSE
0.00%
IPO
Ip Group
LSE
-0.61%
FEN
Frenkel Topping
LSE
0.00%
Trending
TLW
Tullow Oil
LSE
-1.13%